To date, most short peptides are synthesized chemically via solid phase synthesis, which is complex and cost-intense, especially when aiming for large quantities. Since most short peptides are encoded genetically in their original host system, recombinant production is an attractive alter‐ native, which, among other economic advantages, can also easily be scaled up. This also has significant ecological advantages since proble‐ matic solvents being used for solid phase synthesis are not required and customers can be supplied with ‘green’ peptides.
acib’s concept is to use Knallgasbacteria, which naturally fix CO2. Novel strain engineering and gene expression strategies developed by acib specialists facilitate robust and efficient generation of chassis strains that produce peptides at high level. Our key to success for these hydrogen driven processes is the combination of strain engineering for improved CO2 utilization with advanced gas fermentation technologies.
Experts:Prof. Robert Kourist, Dr. Anita Emmerstorfer-Augustin
Investments, Joint Research Projects, Contract Research
Status of the project proposal:Technology Readiness Level 2 (Technology concept formulated)
IPR:Will be generated for our industrial partner / investor
Keywords:Short peptides, Antimicrobial peptides, Peptide Drugs, Pharma, Diagnostics, Vaccines, Hydrogels
Picture credits: Pixabay